Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neogen Corporation (NEOG) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into Neogen’s operations in food safety, animal safety, and related markets, as well as its governance, compensation practices, and financial condition.
Neogen uses current reports on Form 8-K to disclose material events such as the appointment of a new President and Chief Executive Officer, changes in the Chief Financial Officer role, director retirements and appointments, and the results of shareholder votes at its annual meeting. Filings describe executive compensation arrangements, including base salary, annual bonus targets, long-term equity incentives, and performance share unit programs tied to metrics like revenue growth, adjusted EBITDA margin expansion, and cash flow conversion.
Investors can also review 8-K filings that furnish earnings press releases, which summarize quarterly and annual results, segment performance for Food Safety and Animal Safety, and non-GAAP measures such as adjusted EBITDA. These filings complement the company’s financial statements by providing narrative context and reconciliations.
On Stock Titan, NEOG filings are updated as they are posted to EDGAR, and AI-powered summaries can help explain key elements of lengthy documents, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Users can quickly identify disclosures related to executive and director changes, incentive plans, shareholder meeting outcomes, and other governance matters.
This page is a resource for understanding how Neogen describes its strategy, risk factors, performance metrics, and capital structure in its own words through formal SEC filings, with tools to make complex regulatory content more accessible.
Neogen Corp (NEOG) filed a Form 3 for a reporting person serving as a Director. The filing states that no securities are beneficially owned. The event date is 10/24/2025, and the form was filed by one reporting person. The document is signed by Attorney in Fact Christopher Sefcheck on 10/28/2025.
Neogen Corp (NEOG) Form 4: A company director reported transactions dated 10/23/2025. The filer acquired 19,769 shares of common stock at $6.07, bringing directly held shares to 35,084 after the transaction. The filing indicates direct ownership.
The director was also awarded options covering 50,814 shares at an exercise price of $6.07, expiring 10/23/2035. According to the footnote, options and RSUs vest in equal annual installments on each of the first three anniversaries of the grant.
Neogen Corp (NEOG) — Form 4 insider report: A company director reported acquiring 19,769 shares of common stock on 10/23/2025 at $6.07 per share, bringing direct beneficial ownership to 19,769 shares. The filer also received a grant of options for 50,814 shares at a $6.07 exercise price, expiring 10/23/2035. Per the footnote, these awards vest in equal annual installments on each of the first three anniversaries of the grant date.
Neogen (NEOG) filed a Form 4 reporting director equity awards. On 10/23/2025, the reporting person acquired 19,769 shares of common stock at $6.07. Following this, directly held common stock totaled 36,788 shares.
The filing also reports 50,814 stock options granted at an exercise price of $6.07, expiring on 10/23/2035, with 50,814 derivative securities beneficially owned after the transaction. Per the footnote, options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants.
Neogen Corporation (NEOG) director reported equity grants. On 10/23/2025, the insider acquired 19,769 shares of common stock at $6.07 per share, bringing direct beneficial ownership to 43,757 shares. The filer also reported a grant of options to buy 50,814 shares at an exercise price of $6.07, expiring on 10/23/2035. According to the footnote, the options and RSUs vest in equal annual installments on each of the first three anniversaries of the grant date.
Neogen Corp (NEOG) reported an insider equity transaction. A director acquired 19,769 shares of common stock at $6.07 on 10/23/2025 (Transaction Code A). Following this, the director beneficially owned 34,621 common shares directly.
The filing also reports a grant of options to purchase 50,814 shares at an exercise price of $6.07, expiring on 10/23/2035. After the transactions, the director held 50,814 options. The options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants.
Neogen Corp (NEOG) — Form 4 insider report: A director reported an award on 10/23/2025. The filing shows 19,769 shares of common stock acquired (Code A) at $6.07, bringing direct beneficial ownership to 48,469 shares. The director was also granted options to purchase 50,814 shares at an exercise price of $6.07, expiring 10/23/2035. A footnote states the options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants.
Neogen Corp (NEOG) — Form 4 insider activity: A director reported awards dated 10/23/2025. The filing shows an acquisition of 19,769 shares of common stock and a grant of options covering 50,814 shares with a $6.07 exercise price, expiring on 10/23/2035. The form lists 19,769 common shares and 50,814 derivative securities beneficially owned following the transactions, all held directly. Both the options and RSUs vest in equal annual installments on each of the first three anniversaries of the grants.
Neogen (NEOG) reported an insider equity grant by a director on 10/23/2025. The filing shows 50,814 stock options with a $6.07 exercise price expiring on 10/23/2035, and 19,769 shares acquired.
Per the footnote, the options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants. Following these transactions, the director beneficially owned 112,314 shares, held directly.
Neogen Corporation filed an 8-K/A to correct its Annual Meeting results, confirming that Proposal 2 (say‑on‑pay) was approved on October 23, 2025. Shareholder participation was strong, with 195,086,461 of 217,298,626 shares outstanding and entitled to vote present and voted.
Proposal 2 received 167,126,873 For, 17,679,601 Against, 412,667 Abstain, and 9,805,786 broker non‑votes. Shareholders also ratified the appointment of BDO USA, P.C. as auditor with 181,630,320 For, 13,148,285 Against, and 307,856 Abstain. Director nominees Thierry L. Bernard, Mikhael Nassif, Avi Pelossof, and Andrea F. Wainer each received a majority of votes For.